Position in NGNE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$22,483,133
+$6,702,148 QoQ
Shares Held
714,885
-8.7% QoQ
Ownership
3.57%
of shares outstanding
% of Portfolio
3.57%
of 13F equity value
Holder Rank
#9
of 112 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NGNE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Trails Edge Capital Partners, LP holds $624,561,875 across 34 Biotechnology names. NGNE ranks #13 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LBRX |
Lb Pharmaceuticals Inc
|
1,523,022 | $49,429,679 | |
| 2 | NRIX |
Nurix Therapeutics, Inc.
|
1,573,220 | $38,166,317 | |
| 3 | IMCR |
Immunocore Holdings plc
|
1,063,234 | $33,757,679 | |
| 4 | TRAX |
First Tracks Biotherapeutics, Inc.
|
1,514,000 | $30,461,680 | |
| 5 | FDMT |
4D Molecular Therapeutics, Inc.
|
2,227,917 | $29,631,296 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
512,000 | $29,296,640 | |
| 7 | DSGN |
Design Therapeutics, Inc.
|
2,001,282 | $28,958,550 | |
| 8 | XENE |
Xenon Pharmaceuticals Inc.
|
440,000 | $26,558,400 |
All Filings in NGNE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $22,483,133 | 714,885 | Shares | Sole | 2026-08-14 | |
| 2026-06-30 | $22,483,133 | 714,885 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $15,780,985 | 782,787 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $16,171,000 | 785,000 | Shares | Sole | 2026-02-17 | |
| 2025-12-08 | $16,163,150 | 785,000 | Shares | Sole | 2025-12-15 | |
| No filing history on record for this holder in this stock. | ||||||